{"id":2401,"date":"2016-05-01T12:01:00","date_gmt":"2016-05-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen"},"modified":"2016-05-01T12:01:00","modified_gmt":"2016-05-01T10:01:00","slug":"cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/cangrelor-intravenoeser-thrombozytenhemmer-mit-evidenzproblemen","title":{"rendered":"Cangrelor: Intraven\u00f6ser Thrombozytenhemmer mit Evidenzproblemen"},"content":{"rendered":"<p>Cangrelor (Kengrexal\u00ae, The Medicines Company) ist ein direkter und reversibler Adenosin-Diphosphat-P2Y12-Hemmer \u2013 so wie auch Ticagrelor, mit dem es strukturelle und funktionelle chemische Eigenschaften, aber auch die wichtigsten Nebenwirkungen gemeinsam hat: erh\u00f6htes Blutungsrisiko und Dyspnoe. Im Gegensatz zu allen anderen P2Y12-Hemmern wird Cangrelor mittels kontinuierlicher intraven\u00f6ser Infusion verabreicht, wobei die thrombozytenhemmende Wirkung innerhalb von zwei [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cangrelor (Kengrexal\u00ae, The Medicines Company) ist ein direkter und reversibler Adenosin-Diphosphat-P2Y12-Hemmer \u2013 so wie auch Ticagrelor, mit dem es strukturelle und funktionelle chemische Eigenschaften, aber auch die wichtigsten Nebenwirkungen gemeinsam hat: erh\u00f6htes Blutungsrisiko und Dyspnoe. Im Gegensatz zu allen anderen P2Y12-Hemmern wird Cangrelor mittels kontinuierlicher intraven\u00f6ser Infusion verabreicht, wobei die thrombozytenhemmende Wirkung innerhalb von zwei [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[446,495,444,447,1272,450,4754,4759,4758,4757,4756,4755,85,86,498,83,84,87,79,727],"class_list":["post-2401","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acbp","tag-angina-pectoris","tag-aortokoronarer-bypass","tag-aortokoronarer-venenbypass","tag-arteriosklerose","tag-bypass-operation","tag-cangrelor","tag-champion-bridge-studie","tag-champion-pci-studie","tag-champion-phoenix-studie","tag-champion-platform-studie","tag-champion-studie","tag-koronarangiografie","tag-koronarangiographie","tag-koronare-herzkrankheit","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-ptca","tag-thrombozytenaggregationshemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2401"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2401\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}